B. Riley lowered the firm’s price target on Kymera Therapeutics to $16 from $37 and keeps a Neutral rating on the shares post the Q3 report. The analyst believes investors have written off Kymera’s oncology programs due to the minimal efficacy shown. Furthermore, the company discontinued its IRAKIMiD program to focus on immunology indications and is planning to unveil additional targets in January, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KYMR:
- Kymera Therapeutics price target lowered to $30 from $85 at H.C. Wainwright
- Kymera Therapeutics to present data from Phase 1 trial of KT-333
- Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics reports Q3 EPS (90c), consensus (72c)
- Kymera Therapeutics announces first patient dosed in Phase 2 trial of KT-474
Questions or Comments about the article? Write to editor@tipranks.com